RxDoctor Payments Data

Amanda Guidon, MD

Neurology · Boston, MANPI 1639344583

Payments from drug & device makers

$151,748in general payments, 2019–2025

Across 65 payments — averaging $2334.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$55K
  • UCB, Inc.$43K
  • AstraZeneca$29K
  • Janssen Research & Development, LLC$9K
  • UCB SA$8K
  • Amgen$4K
  • plus $4K from 3 others

What the payments were for

  • Consulting fees$84,32896%
  • Travel & lodging$2,9333%
  • Food & beverage$9911%

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argenx US, Inc.6$55,363
UCB, Inc.25$43,001
AstraZeneca20$28,816
Janssen Research & Development, LLC4$8,817
UCB SA1$8,000
Amgen3$3,513
UCB Biosciences Inc.1$3,453
Regeneron4$484
Novartis1$302

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$151,748 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$92,312
Medicare patients
380
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZilbrysqZilucoplan Sodium46$1,518,000
VyvgartEfgartigimod Alfa-Fcab14$935,089
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc11$581,343
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5030$496,701
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$155,812
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5032$105,927
Mycophenolate Mofetil109$28,192
Pyridostigmine Bromide107$10,470
Azathioprine56$4,363
Prednisone98$767
Gabapentin28$443
Potassium Chloride11$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Zilbrysq$43,001$1,518,00046 claims
Argenx US, Inc.Vyvgart, Vyvgart Hytrulo$55,363$1,516,43225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →